Robert T Dorr

  • 9198 Citations
  • 49 h-Index
1976 …2016

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

  • 9198 Citations
  • 49 h-Index
  • 220 Article
  • 7 Letter
  • 7 Review article
  • 5 Comment/debate
Article

1,4-disubstituted anthracene antitumor agents

Iyengar, B. S., Dorr, R. T., Alberts, D. S., Sólyom, A. M., Krutzsch, M. & Remers, W. A., Nov 20 1997, In : Journal of Medicinal Chemistry. 40, 23, p. 3734-3738 5 p.

Research output: Contribution to journalArticle

25 Scopus citations
37 Scopus citations

2-Substituted 1,2-Dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A New Class of Antitumor Agent

Sami, S. M., Dorr, R. T., Alberts, D. S. & Remers, W. A., Jan 1 1993, In : Journal of Medicinal Chemistry. 36, 6, p. 765-770 6 p.

Research output: Contribution to journalArticle

64 Scopus citations
30 Scopus citations

Absorption enhancement of melanotan-l: Comparison of the caco-2 and rat in situ models

Surendran, N., Ugwu, S. O., Nguyen, L. D., Sterling, E. J., Dorr, R. T. & Blanchard, J., Jan 1 1995, In : Drug Delivery. 2, 1, p. 49-55 7 p.

Research output: Contribution to journalArticle

6 Scopus citations

A comparison of HPLC and bioassay methods for plasma melanotan‐II (MT‐II) determination: Application to a pharmacokinetic study in rats

Ugwu, S. O., Blanchard, J., Nguyen, L. D., Hadley, M. E. & Dorr, R. T., Jul 1994, In : Biopharmaceutics & Drug Disposition. 15, 5, p. 383-390 8 p.

Research output: Contribution to journalArticle

7 Scopus citations

Additional Nucleotide Derivatives of Mitosenes. Synthesis and Activity against Parental and Multidrug Resistant L1210 Leukemia

Iyengar, B. S., Remers, W. A. & Dorr, R. T., Jul 1 1991, In : Journal of Medicinal Chemistry. 34, 7, p. 1947-1951 5 p.

Research output: Contribution to journalArticle

10 Scopus citations

Administration of melanotropic peptides during gestation in the rodent

Dawson, B. V., Ford, C. A., Holloway, H., Dorr, R. T. & Johnson, P., Jan 29 1993, In : Toxicology. 77, 1-2, p. 91-101 11 p.

Research output: Contribution to journalArticle

5 Scopus citations

Adult rat myocardial slices: A tool for studies of comparative cardiotoxicity

Parrish, A. R., Dorr, R. T., Gandolfi, A. J. & Brendel, K., Dec 1994, In : Toxicology in Vitro. 8, 6, p. 1233-1237 5 p.

Research output: Contribution to journalArticle

8 Scopus citations

Alkylation of DNA by C-10 of 2,7-Diaminomitosene

Iyengar, B. S., Remers, W. A., Dorr, R. T. & Shipp, N. G., Jan 1990, In : Journal of Medicinal Chemistry. 33, 1, p. 253-257 5 p.

Research output: Contribution to journalArticle

24 Scopus citations

Allopurinol kinetics and bioavailability - Intravenous, oral and rectal administration

Appelbaum, S. J., Mayersohn, M., Dorr, R. T. & Perrier, D., Apr 1982, In : Cancer Chemotherapy And Pharmacology. 8, 1, p. 93-98 6 p.

Research output: Contribution to journalArticle

43 Scopus citations

Alpha‐globulins suppress human leukocyte tumor necrosis factor secretion

Scuderi, P., Dorr, R. T., Liddil, J. D., Finley, P. R., Meltzer, P., Raitano, A. B. & Rybski, J., May 1989, In : European Journal of Immunology. 19, 5, p. 939-942 4 p.

Research output: Contribution to journalArticle

44 Scopus citations
47 Scopus citations

Analogues of amonafide and azonafide with novel ring systems

Sami, S. M., Dorr, R. T., Alberts, D. S., Solyom, A. M. & Remers, W. A., Aug 10 2000, In : Journal of Medicinal Chemistry. 43, 16, p. 3067-3073 7 p.

Research output: Contribution to journalArticle

60 Scopus citations

Analytical and biological inequivalence of two commercial formulations of the antitumor agent bleomycin

Dorr, R. T., Meyers, R., Snead, K. & Liddil, J. D., Jun 22 1998, In : Cancer Chemotherapy And Pharmacology. 42, 2, p. 149-154 6 p.

Research output: Contribution to journalArticle

8 Scopus citations

Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function

Kintzel, P. E. & Dorr, R. T., Jan 1995, In : Cancer Treatment Reviews. 21, 1, p. 33-64 32 p.

Research output: Contribution to journalArticle

286 Scopus citations

Antidotes to vesicant chemotherapy extravasations

Dorr, R. T., Mar 1990, In : Blood Reviews. 4, 1, p. 41-60 20 p.

Research output: Contribution to journalArticle

118 Scopus citations

Antidote studies of vinorelbine-induced skin ulceration in the mouse

Dorr, R. T. & Bool, K. L., Jul 1 1995, In : Cancer Chemotherapy And Pharmacology. 36, 4, p. 290-292 3 p.

Research output: Contribution to journalArticle

13 Scopus citations

Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro

Hersh, E. M., Gschwind, C. R., Taylor, C. W., Dorr, R. T., Taetle, R. & Salmon, S. E., Aug 19 1992, In : Journal of the National Cancer Institute. 84, 16, p. 1238-1244 7 p.

Research output: Contribution to journalArticle

33 Scopus citations

Anti-tumor activity and mechanism of action for a cyanoaziridine- derivative, AMP423

Dorr, R. T., Wisner, L., Samulitis, B. K., Landowski, T. H. & Remers, W. A., Apr 1 2012, In : Cancer Chemotherapy And Pharmacology. 69, 4, p. 1039-1049 11 p.

Research output: Contribution to journalArticle

7 Scopus citations

Antitumor Activity and Murine Pharmacokinetics of Parenteral Acronycine

Dorr, R. T., Liddil, J. D., Von Hoff, D. D., Soble, M. & Osborne, C. K., Jan 15 1989, In : Cancer Research. 49, 2, p. 340-344 5 p.

Research output: Contribution to journalArticle

81 Scopus citations

Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor

Dorr, R. T., Dvorakova, K., Snead, K., Alberts, D. S., Salmon, S. E. & Pettit, G. R., Jan 1 1996, In : Investigational New Drugs. 14, 2, p. 131-137 7 p.

Research output: Contribution to journalArticle

59 Scopus citations

A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma

Weber, J. S., Samlowski, W. E., Gonzalez, R., Ribas, A., Stephenson, J., O'Day, S., Sato, T., Dorr, R., Grenier, K. & Hersh, E., Aug 1 2010, In : Cancer. 116, 15, p. 3683-3691 9 p.

Research output: Contribution to journalArticle

16 Scopus citations

A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease

Miller, T. P., Chase, E. M., Dorr, R., Dalton, W. S., Lam, K. S. & Salmon, S. E., Jan 1 1998, In : Anti-cancer drugs. 9, 2, p. 135-140 6 p.

Research output: Contribution to journalArticle

25 Scopus citations

A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors

Taylor, C. W., Dorr, R. T., Fanta, P., Hersh, E. M. & Salmon, S. E., Jul 31 2001, In : Cancer Chemotherapy And Pharmacology. 47, 1, p. 83-88 6 p.

Research output: Contribution to journalArticle

39 Scopus citations

A phase i study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer

Cohen, S. J., Zalupski, M. M., Modiano, M. R., Conkling, P., Patt, Y. Z., Davis, P., Dorr, R. T., Boytim, M. L. & Hersh, E. M., Jul 1 2010, In : Cancer Chemotherapy And Pharmacology. 66, 2, p. 287-294 8 p.

Research output: Contribution to journalArticle

19 Scopus citations

A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies

Lopez, A. M., Ketchum, M., Nichols, H., Xu, M. J., Peng, Y. M., Dorr, R. & Alberts, D. S., Jan 1 2000, In : Cancer Chemotherapy And Pharmacology. 46, 5, p. 411-415 5 p.

Research output: Contribution to journalArticle

A phase i trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer

Moulder, S., Dhillon, N., Ng, C., Hong, D., Wheler, J., Naing, A., Tse, S., La Paglia, A., Dorr, R., Hersh, E., Boytim, M. & Kurzrock, R., Oct 1 2010, In : Investigational New Drugs. 28, 5, p. 634-640 7 p.

Research output: Contribution to journalArticle

23 Scopus citations

A phase I trial of β-all-trans-retinoic acid delivered via a collagen sponge and a cervical cap for mild or moderate intraepithelial cervical neoplasia

Meyskens, F. L., Graham, V., Chvapil, M., Dorr, R. T., Alberts, D. S. & Surwit, E. A., Dec 1 1983, In : Journal of the National Cancer Institute. 71, 5, p. 921-925 5 p.

Research output: Contribution to journalArticle

63 Scopus citations

Approaches to reducing toxicity of parenteral anticancer drug formulations using cyclodextrins

Bhardwaj, R., Dorr, R. T. & Blanchard, J., May 1 2000, In : PDA Journal of Pharmaceutical Science and Technology. 54, 3, p. 233-239 7 p.

Research output: Contribution to journalArticle

28 Scopus citations

Association of Lysosomal Activity with Sensitivity and Resistance to Tumor Necrosis Factor in Murine L929 Cells

Liddil, J. D., Dorr, R. T. & Scuderi, P., Mar 15 1989, In : Cancer Research. 49, 10, p. 2722-2728 7 p.

Research output: Contribution to journalArticle

34 Scopus citations
83 Scopus citations

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study

List, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Persons, D. L., Slovak, M. L., Dorr, R., Karanes, C., Hynes, H. E., Doroshow, J. H., Shurafa, M. & Appelbaum, F. R., Dec 1 2001, In : Blood. 98, 12, p. 3212-3220 9 p.

Research output: Contribution to journalArticle

334 Scopus citations

Biochemical effects and toxicity of mitoxantrone in cultured heart cells

Shipp, N. G. & Dorr, R. T., Oct 7 1991, In : Advances in experimental medicine and biology. 283, p. 821-825 5 p.

Research output: Contribution to journalArticle

6 Scopus citations

Biologic activity of a nucleotide conjugate between mitomycin c and cytarabine monophosphate

Dorr, R. T. & James, D., Sep 1 1994, In : Nucleosides and Nucleotides. 13, 8, p. 1655-1667 13 p.

Research output: Contribution to journalArticle

2 Scopus citations

Bisantrene solubility and skin toxicity studies: Efficacy of sodium bicarbonate as a local ulceration antidote

Dorr, R. T., Peng, Y. M. & Alberts, D. S., Dec 1 1984, In : Investigational New Drugs. 2, 4, p. 351-357 7 p.

Research output: Contribution to journalArticle

3 Scopus citations

Bleomycin compatibility with selected intravenous medications

Dorr, R. T., Peng, Y. M. & Alberts, D. S., Jan 1 1982, In : Journal of Medicine. 13, 1-2, p. 121-130 10 p.

Research output: Contribution to journalArticle

1 Scopus citations

Bleomycin pharmacology: Mechanism of action and resistance, and clinical pharmacokinetics

Dorr, R. T., Apr 1992, In : Seminars in Oncology. 19, 2 SUPPL. 5, p. 3-8 6 p.

Research output: Contribution to journalArticle

79 Scopus citations

Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol, WR-1065, in vitro

Dorr, R. T., Lagel, K. & McLean, S., 1996, In : European Journal of Cancer. 32, SUPPL. 4, p. S21-S25

Research output: Contribution to journalArticle

39 Scopus citations

Cardiotoxicity of mitomycin A, mitomycin C, and seven N7 analogs in vitro

Dorr, R. T., Shipp, N. G., Liddil, J. D., Iyengar, B. S., Kunz, K. R. & Remers, W. A., Jan 1 1992, In : Cancer Chemotherapy And Pharmacology. 31, 1, p. 1-5 5 p.

Research output: Contribution to journalArticle

4 Scopus citations

Case report: topical DMSO for mitomycin-C-induced skin ulceration.

Alberts, D. S. & Dorr, R. T., May 1 1991, In : Oncology nursing forum. 18, 4, p. 693-695 3 p.

Research output: Contribution to journalArticle

38 Scopus citations

Characterization of a membrane-active anti-tumor agent, UA8967

Dorr, R. T., Samulitis, B. K., Wisner, L., Han, H., Zhao, Y., Beroza, P., Damodaran, K., Igarashi, S., Landowski, T. H. & Von Hoff, D. D., Jun 1 2013, In : Investigational New Drugs. 31, 3, p. 576-586 11 p.

Research output: Contribution to journalArticle

1 Scopus citations

Characterization of a mitomycin C (MMC) resistant L-1210 cell line

Dorr, R. T., Liddil, J. D. & Trent, J. M., Jan 1 1985, In : Proceedings of the American Association for Cancer Research. VOL. 26, p. No. 1358

Research output: Contribution to journalArticle

3 Scopus citations
31 Scopus citations

Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer

Shaw, A. Y., Henderson, M. C., Flynn, G., Samulitis, B., Han, H., Stratton, S. P., Chow, H. H. S., Hurley, L. H. & Dorr, R. T., Nov 1 2009, In : Journal of Pharmacology and Experimental Therapeutics. 331, 2, p. 636-647 12 p.

Research output: Contribution to journalArticle

27 Scopus citations

Chemical Basis for the Biological Activity of Imexon and Related Cyanoaziridines

Iyengar, B. S., Dorr, R. T. & Remers, W. A., Jan 1 2004, In : Journal of Medicinal Chemistry. 47, 1, p. 218-223 6 p.

Research output: Contribution to journalArticle

47 Scopus citations

Chemistry and pharmacology of imexon and related cyanoaziridines

Remers, W. A. & Dorr, R. T., Dec 24 2012, In : Current medicinal chemistry. 19, 33, p. 5745-5753 9 p.

Research output: Contribution to journalArticle

5 Scopus citations

Chemoprevention of human actinic keratoses by topical 2-(Difluoromethyl)-dl-ornithine

Alberts, D. S., Dorr, R. T., Einspahr, J. G., Aickin, M., Saboda, K., Xu, M. J., Peng, Y. M., Goldman, R., Foote, J. A., Warneke, J. A., Salasche, S., Roe, D. J. & Bowden, G. T., Dec 1 2000, In : Cancer Epidemiology Biomarkers and Prevention. 9, 12, p. 1281-1286 6 p.

Research output: Contribution to journalArticle

78 Scopus citations

Chemoprotectants for cancer chemotherapy

Dorr, R. T., Feb 1991, In : Seminars in Oncology. 18, 1 SUPPL. 2, p. 48-58 11 p.

Research output: Contribution to journalArticle

54 Scopus citations

Choosing a sunscreen

Relling, M. V. & Dorr, R. T., Dec 1 1983, In : Arizona Medicine. 40, 8, p. 550-554 5 p.

Research output: Contribution to journalArticle